prof. RNDr. Vladimír KRYŠTOF, Ph.D.
Telefon:
585634854
E-mail:
WWW:
Pracoviště:
Katedra experimentální biologie
Org. jednotka:
Přírodovědecká fakulta
Adresa:
Šlechtitelů 27 A (hlavní budova)
Místnost:
3.23
Pracovní zařazení:
Profesor
Odborné aktivity:
Medicinální a biologická chemie. Biologie nádorové buňky.
Funkce a členství v akademických a dalších orgánech UP i mimo ni:
- Člen VR fakulty (1. 4. 2018 – 9. 3. 2022)
- Vedoucí katedry/ústavu/kliniky (1. 1. 2021 – )
- Člen oborové rady (9. 7. 2021 – 8. 8. 2028)
Vědecká společnost
- Česká společnost chemická (člen, 2005–)
- European Association for Cancer Research (člen, 2006–)
- Česká společnost experimentální biologie rostlin (člen, 2004–)
- Phytochemical Society of Europe (člen, 2012–)
Redakční rada
- European Journal of Medicinal Chemistry (člen, 2021–)
- European Journal of Medicinal Chemistry Reports (člen, 2022–)
Jiné komise a orgány
- Grantová agentura České republiky, člen hodnoticího panelu (P303 Fyziologické obory, farmakologie, neurovědy a toxikologie) (člen, 2017–2020)
- Grantová agentura České republiky, člen hodnoticího panelu (P304 Nádorová biologie, experimentální onkologie, morfologické obory a patologie) (člen, 2020–2021)
ČLÁNEK
Mik V., Benz LS., Voller J., Kryštof V.
A patent review of Mpro protease inhibitors for the treatment of COVID-19 infections (2020 – present).
EXPERT OPINION ON THERAPEUTIC PATENTS.
2025.
Řezníčková E., Bárta O., Milde D., Kryštof V., Štarha P.
Anticancer dinuclear Ir(III) complex activates Nrf2 and interferes with NAD(H) in cancer cells.
JOURNAL OF INORGANIC BIOCHEMISTRY.
2025.
Škerlová J., Krejčiříková V., Peřina M., Vojáčková V., Kryštof V., Jorda R.
CDK2-based CDK7 mimic as a tool for structural analysis: Biochemical validation and crystal structure with SY5609.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES.
2025.
Eldehna WM., Tawfik HO., Veselá D., Vojáčková V., Krňávková P., Kryštof V., Abdel-Aziz HA.
Development of New Pyrazolo [3,4-b]Pyridine Derivatives as Potent Anti-Leukemic Agents and Topoisomerase IIα Inhibitors with Broad-Spectrum Cytotoxicity.
Pharmaceuticals.
2025.
Markuliak M., Kos D., Vojáčková V., Kryštof V., Jampílek J.
Preparation and biological activity of isoperrottetin A and its phosphonium salts derivatives.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES.
2025.
Górecki L., Řezníčková E., Kryštof V.
Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review.
EXPERT OPINION ON THERAPEUTIC PATENTS.
2025.
Rataj J., Górecki L., Muthna D., Kryštof V., Čečková M.
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges.
BIOMEDICINE & PHARMACOTHERAPY.
2025.
Ferchaud N., Kopečný D., Peřina M., Kryštof V., Machover D.
The methioninase from the alkalithermophile Thermobrachium celere possesses suitable properties for treatment of cancer.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES.
2025.
Kos J., Strhársky T., Tosso R., Vojáčková V., Kryštof V., Jampílek J.
Trifluoromethylcinnamanilides – Effective dual inhibitors of Mycobacterium smegmatis and Plasmodium falciparum.
BIOORGANIC CHEMISTRY.
2025.
Cabezas D., Delgado T., Sepúlveda G., Krňávková P., Vojáčková V., Kryštof V., Strnad M., Mella J.
3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib.
Pharmaceuticals.
2025.
Maláriková D., Jorda R., Kupcová K., Kryštof V., Strnad M., Klener P.
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.
Experimental Hematology and Oncology.
2024.
Moradi M., Mousavi A., Řezníčková E., Peřina M., Vojáčková V., Jorda R., Grúz J., Kryštof V., Foroumadi A.
Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2024.
Delgado T., Veselá D., Dostálová H., Kryštof V., Vojáčková V., Jorda R., Strnad M., Salas CO.
New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs.
Pharmaceutics.
2024.
Dostálová H., Kryštof V.
Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
Hematological Oncology.
2024.
Varvuolytė G., Řezníčková E., Bieliauskas A., Vojáčková V., Opichalová A., Žukauskaite A., Kryštof V.
Synthesis and photodynamic activity of new 5-[(E)-2-(3-alkoxy-1-phenyl-1H-pyrazol-4-yl)ethenyl]-2-phenyl-3H-indoles.
ARCHIV DER PHARMAZIE.
2024.
Varvuloitė G., Řezníčková E., Krikštolė S., Malina L., Vojáčková V., Duben Z., Kolářová H., Žukauskaite A., Kryštof V., Šačkus A.
Synthesis and photo-induced anticancer activity of new 2-phenylethenyl-1H-benzo[e]indole dyes.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2024.
Kovalová M., Baraka JP., Mik V., Jorda R., Kryštof V.
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
EXPERT OPINION ON THERAPEUTIC PATENTS.
2023.
Dostálová H., Jorda R., Řezníčková E., Kryštof V.
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines.
INVESTIGATIONAL NEW DRUGS.
2023.
Ganai AM., Pathan TK., Mohite SB., Vojáčková V., Řezníčková E., Kozlanská K., Kryštof V.
Design and synthesis of novel 1,2,4-triazolo[4,3-b]pyridazine derivatives with anti-cancer activity.
JOURNAL OF MOLECULAR STRUCTURE.
2023.
Kovalová M., Havlíček L., Djukic S., Peřina M., Pospíšil T., Řezníčková E., Jorda R., Kryštof V.
Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
BIOMEDICINE & PHARMACOTHERAPY.
2023.
Löffelmann M., Škrott Z., Majera D., Štarha P., Kryštof V., Mistrík M.
Identification of novel dithiocarbamate-copper complexes targeting p97/ NPL4 pathway in cancer cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2023.
Břehová P., Řezníčková E., Škach K., Jorda R., Vojáčková V., Kovalová M., Kinnertová M., Gucký T., Kryštof V.
Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping.
JOURNAL OF MEDICINAL CHEMISTRY.
2023.
Vlková K., Padrtová R., Gucký T., Peřina M., Řezníčková E., Kryštof V.
Synthesis and biological activity evaluation of novel 3,5,7-trisubstituted pyrazolo[1,5-a]pyrimidines.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS.
2023.
Shaldam MA., Veselá D., El-Haggar R., Vojáčková V., Kryštof V.
2,4-Diaryl-pyrimido[1,2-a]benzimidazole derivatives as novel anticancer agents endowed with potent anti-leukemia activity: Synthesis, biological evaluation and kinase profiling.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2023.
Rudolfová J., Kryštof V., Nečas M., Vícha R., Rouchal M.
Adamantane-Substituted Purine Nucleosides: Synthesis, Host–Guest Complexes with β-Cyclodextrin and Biological Activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2022.
Bertrand J., Dostálová H., Kryštof V., Jorda R.
Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.
Pharmaceutics.
2022.
Porubský M., Řezníčková E., Křupková S., Kryštof V., Hlaváč J.
Development of fluorescent dual-FRET probe for simultaneous detection of caspase-8 and caspase-9 activities and their relative quantification.
BIOORGANIC CHEMISTRY.
2022.
Ganai AM., Pathan TK., Merugu SR., Kozlanská K., Vojáčková V., Kryštof V.
Development of pyrimidine-cinnamamide hybrids as potential anticancer agents: A rational design approach.
JOURNAL OF MOLECULAR STRUCTURE.
2022.
Řezníčková E., Krajčovičová S., Peřina M., Kovalová M., Soural M., Kryštof V.
Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC).
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2022.
Opitz A., Seitz L., Kryštof V.
Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's disease.
Future Medicinal Chemistry.
2022.
Barghash RF., Eldehna WM., Kovalová M., Vojáčková V., Kryštof V., Abdel-Aziz HA.
One-pot three-component synthesis of novel pyrazolo[3,4-b]pyridines as potent antileukemic agents.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2022.
Vlková K., Gucký T., Peřina M., Řezníčková E., Kryštof V.
Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS.
2022.
Tomanová M., Kozlanská K., Jorda R., Jedinák L., Havlíková T., Řezníčková E., Peřina M., Klener P., Dolníková A., Cankař P., Kryštof V.
Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2022.
Razmienė B., Vojáčková V., Řezníčková E., Malina L., Kubala M., Bajgar R., Kolářová H., Žukauskaite A., Kryštof V.
Synthesis of N-aryl-2,6-diphenyl-2H-pyrazolo[4,3-c]pyridin-7-amines and their photodynamic properties in the human skin melanoma cell line G361.
BIOORGANIC CHEMISTRY.
2022.
Toman D., Jorda R., Ajani H., Kryštof V., Cankař P.
Synthesis of 4-styrylpyrazoles and Evaluation of their Inhibitory Effects on Cyclin-dependent Kinases.
Medicinal Chemistry.
2022.
Jorda R., Havlíček L., Peřina M., Vojáčková V., Pospíšil T., Grúz J., Strnad M., Kryštof V.
3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders.
JOURNAL OF MEDICINAL CHEMISTRY.
2022.
Rouchal M., Rudolfová J., Kryštof V., Vojáčková V.
Adamantane-Substituted Purines and Their beta-Cyclodextrin Complexes: Synthesis and Biological Activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2021.
Schade N., Koch P., Ansideri F., Kryštof V., Holzer M., Hilgeroth A.
Evaluation of Novel Substituted Furopyridines as Inhibitors of Protein Kinases Related to Tau Pathology in Alzheimer's Disease.
Medicinal Chemistry.
2021.
Hendrychová D., Jorda R., Kryštof V.
How selective are clinical CDK4/6 inhibitors?
MEDICINAL RESEARCH REVIEWS.
2021.
Jansa J., Jorda R., Škerlová J., Peřina M., Řezníčková E., Heger T., Gucký T., Kryštof V.
Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2021.
Jorda R., Molitorová V., Vojáčková V., Řezníčková E., Kryštof V.
Pseudopeptides with aldehyde or vinylsulfone warheads: Synthesis and antiproteasomal activity.
BIOORGANIC CHEMISTRY.
2021.
Razmienė B., Řezníčková E., Dambrauskienė V., Ostruszka R., Kubala M., Žukauskaite A., Kryštof V.
Synthesis and Antiproliferative Activity of 2,4,6,7-Tetrasubstituted-2H-pyrazolo[4,3-c]pyridines.
MOLECULES.
2021.
Krajčovičová S., Jorda R., Vanda D., Soural M., Kryštof V.
1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2021.
Dayal N., Řezníčková E., Hernandez DE., Peřina M., Vojáčková V., Kryštof V., Jorda R.
3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo.
JOURNAL OF MEDICINAL CHEMISTRY.
2021.
Štětková M., Growková K., Fojtík P., Jorda R., Kryštof V.
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Cell Death & Disease.
2020.
Špičáková A., Kraus P., Gucký T., Kryštof V., Strnad M., Bazgier V., Otyepka M., Kubíčková V., Poruba M., Rácová Z., Zapletalová I., Anzenbacher P.
In vitro and in silico studies of interaction of synthetic 2,6,9-trisubstituted purine kinase inhibitors BPA-302, BP-21 and BP-117 with liver drug-metabolizing cytochromes P450.
PHYSIOLOGICAL RESEARCH.
2020.
Bertrand J., Dostálová H., Kryštof V., Jorda R.
New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.
BIOORGANIC CHEMISTRY.
2020.
Jorda R., Magar P., Hendrychová D., Kryštof V.
Novel modified leucine and phenylalanine dipeptides modulate viability and attachment of cancer cells.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2020.
Köprülüoglu C., Dejmek M., Šála M., Ajani HB., Jorda R., Kryštof V., Hobza P.
Optimization of norbornyl-based carbocyclic nucleoside analogs as cyclin-dependent kinase 2 inhibitors.
JOURNAL OF MOLECULAR RECOGNITION.
2020.
Salas CO., Zarate AM., Kryštof V., Hendrychová D., Jorda R.
Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
2020.
Jorda R., Krajčovičová S., Králová P., Soural M., Kryštof V.
Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2020.
Said MA., Eldehna WM., Nocentini A., Kryštof V.
Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2020.
Varvuolyté G., Malina L., Bieliauskas A., Hošíková B., Simerská H., Kolářová H., Kleiziené N., Kryštof V., Šačkus A., Žukauskaite A.
Synthesis and photodynamic properties of pyrazole-indole hybrids in the human skin melanoma cell line G361.
DYES AND PIGMENTS.
2020.
Řezníčková E., Gucký T., Kováčová V., Ajani H., Jorda R., Kryštof V.
Activity of 2,6,9-trisubstituted purines as potent PDGFR alpha kinase inhibitors with antileukaemic activity.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Kubczak M., Szustka A., Błoński JZ., Gucký T., Kryštof V.
Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors.
Molecular Medicine Reports.
2019.
Krajčovičová S., Jorda R., Hendrychová D., Kryštof V., Soural M.
Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC).
CHEMICAL COMMUNICATIONS.
2019.
Abo-Ashour MF., Eldehna WM., Nocentini A., Kryštof V., Jorda R.
3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Jorda R., Havlíček L., Šturc A., Peřina M., Pospíšil T., Široká J., Urbánek L., Strnad M., Kryštof V.
3,5,7-Substituted Pyrazolo[4,3-d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
JOURNAL OF MEDICINAL CHEMISTRY.
2019.
Voller J., Zahajská L., Plíhalová L., Jeřábková J., Burget D., Pataki AC., Kryštof V., Zatloukal M., Brábek J., Rosel D., Mik V., Tkáč M., Pospíšil T., Gucký T., Doležal K., Strnad M.
6-Substituted purines as ROCK inhibitors with anti-metastatic activity.
BIOORGANIC CHEMISTRY.
2019.
Liu R., Rongxia EH., Waltenberger B., Blazevic T., Schachner D., Jiang B., Kryštof V., Liu W., Schwaiger S., Pena-Rodriguez LM., Breuss JM., Stuppner H., Dirsch VM., Atanasov AG.
Constituents of Mediterranean Spices Counteracting Vascular Smooth Muscle Cell Proliferation: Identification and Characterization of Rosmarinic Acid Methyl Ester as a Novel Inhibitor.
MOLECULAR NUTRITION & FOOD RESEARCH.
2018.
Gucký T., Řezníčková E., Radošová Muchová T., Jorda R., Klejová Z., Malínková V., Berka K., Bazgier V., Ajani HB., Lepšík M., Divoký V., Kryštof V.
Discovery of N-2-(4-Amino-cyclohexyl)-9-cyclopentyl-N-6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations.
JOURNAL OF MEDICINAL CHEMISTRY.
2018.
Jorda R., Hendrychová D., Voller J., Řezníčková E., Gucký T., Kryštof V.
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
JOURNAL OF MEDICINAL CHEMISTRY.
2018.
Ajani HB., Jansa J., Köprülüoglu C., Hobza P., Kryštof V., Lyčka A., Lepšík M.
Imidazo[1,2-c]pyrimidin-5(6H)-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring.
JOURNAL OF MOLECULAR RECOGNITION.
2018.
Široká J., Čečková M., Urbánek L., Kryštof V., Gucký T., Hofman J., Strnad M., Štaud F.
LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES.
2018.
Jorda R., Bučková Z., Řezníčková E., Bouchal J., Kryštof V.
Selective inhibition reveals cyclin-dependent kinase 2 as another kinase that phosphorylates the androgen receptor at serine 81.
Biochimica et Biophysica Acta - Molecular Cell Research.
2018.
Milisiunaite V., Arbaciauskiene E., Řezníčková E., Jorda R., Malínková V., Žukauskaite A., Holzer W., Sackus A., Kryštof V.
Synthesis and anti-mitotic activity of 2,4-or 2,6-disubstituted- and 2,4,6-trisubstituted-2H-pyrazolo[4,3-c]pyridines.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.
2018.
Cherukupalli S., Chandrasekaran B., Kryštof V., Aleti RR., Sayyad N., Merugu SR., Kushwaha ND., Karpoormath R.
Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
BIOORGANIC CHEMISTRY.
2018.
Lasák P., Motyka K., Kryštof V., Stýskala J.
Synthesis, Bacteriostatic and Anticancer Activity of Novel Phenanthridines Structurally Similar to Benzo[c]phenanthridine Alkaloids.
MOLECULES.
2018.
Krajčovičová S., Gucký T., Hendrychová D., Kryštof V., Soural M.
A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinases Inhibitors.
Journal of Organic Chemistry.
2017.
Řezníčková E., Tenora L., Pospíšilová P., Galeta J., Jorda R., Berka K., Majer P., Potáček M., Kryštof V.
ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethy1-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
European Journal of Medicinal Chemistry.
2017.
Jorda R., Lopes SMM., Řezníčková E., Kryštof V., Pinho e. Melo TMVD.
Biological Evaluation of Dipyrromethanes in Cancer Cell Lines: Antiproliferative and Pro-apoptotic Properties.
ChemMedChem.
2017.
Hylsová M., Carbain B., Fanfrlík J., Musilová L., Haldar S., Koepruelueoglu C., Ajani H., Brahmkshatriya PS., Jorda R., Kryštof V., Hobza P., Echalier A., Paruch K., Lepšík M.
Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
European Journal of Medicinal Chemistry.
2017.
Xavier NM., Porcheron A., Batista D., Jorda R., Řezníčková E., Kryštof V., Oliveira CM.
Exploitation of new structurally diverse D-glucuronamide-containing N-glycosyl compounds: synthesis and anticancer potential.
Organic & Biomolecular Chemistry.
2017.
Cavallaro V., Řezníčková E., Jorda R., Alza NP., Murray AP., Kryštof V.
Semisynthetic Esters of 17-Hydroxycativic Acid with in Vitro Cytotoxic Activity against Leukemia Cell Lines.
Biological and Pharmaceutical Bulletin.
2017.
Nekardová M., Vymětalová L., Khirsariya P., Kováčová S., Hylsová M., Jorda R., Kryštof V., Fanfrlík J., Hobza P., Paruch K.
Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.
ChemPhysChem.
2017.
Dušek J., Imramovský A., Pauk K., Jorda R., Řezníčková E., Kryštof V.
Synthesis and Antiproliferative Activities of Novel O-Benzyl Salicylamide Derivatives.
Letters in Drug Design and Discovery.
2017.
Xavier NM., Goncalves-Pereira R., Jorda R., Řezníčková E., Kryštof V., Oliveira CM.
Synthesis and antiproliferative evaluation of novel azido nucleosides and their phosphoramidate derivatives.
Pure and Applied Chemistry.
2017.
Jorda R., Dušek J., Řezníčková E., Pauk K., Magar PP., Imramovský A., Kryštof V.
Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
European Journal of Medicinal Chemistry.
2017.
Malínková V., Řezníčková E., Jorda R., Gucký T., Kryštof V.
Trisubstituted purine inhibitors of PDGFR alpha and their antileukemic activity in the human eosinophilic cell line EOL-1.
Bioorganic & Medicinal Chemistry.
2017.
Zhang S., Ulrich M., Gromnicka A., Havlíček L., Kryštof V., Jorda R., Strnad M., Vollmar AM., Zahler S.
Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.
British Journal of Pharmacology.
2016.
Tenora L., Galeta J., Řezníčková E., Kryštof V., Potáček M.
Application of Pd-Catalyzed Cross-Coupling Reactions in the Synthesis of 5,5-Dimethy1-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles that Inhibit ALK5 Kinase.
Journal of Organic Chemistry.
2016.
Bhambra AS., Edgar M., Elsegood MR., Li Y., Weaver GW., Arroo RR., Yardley V., Burrell-Saward H., Kryštof V.
Design, synthesis and antitrypanosomal activities of 2,6-disubstituted-4,5,7-trifluorobenzothiophenes.
European Journal of Medicinal Chemistry.
2016.
Wrobel TM., Kielbus M., Kaczor AA., Kryštof V., Karczmarzyk Z., Wysocki W., Fruzinski A., Krol SK., Grabarska A., Stepulak A., Matosiuk D.
Discovery of nitroaryl urea derivatives with antiproliferative properties.
Journal of Enzyme Inhibition and Medicinal Chemistry.
2016.
Allegri L., Baldan F., Mio C., Puppin C., Diego R., Kryštof V., Damante G.
Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
Oncology Reports.
2016.
Bhambra AS., Edgar M., Elsegood MR., Horsburgh L., Kryštof V., Lucas PD., Mojally M., Teat SJ., Warwick TG., Weaver GW., Zeinali F.
Novel fluorinated benzimidazole-based scaffolds and their anticancer activity in vitro.
Journal of Fluorine Chemistry.
2016.
Pachníková G., Uldrijan S., Imramovský A., Kryštof V., Slaninová I.
Substituted 2-hydroxy-N-(arylalkyl)benzamide sensitizes cancer cells to metabolic stress by disrupting actin cytoskeleton and inhibiting autophagic flux.
Toxicology in Vitro.
2016.
Baltus CB., Jorda R., Marot C., Berka K., Bazgier V., Kryštof V., Prie G., Viaud-Massuard M.
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
European Journal of Medicinal Chemistry.
2016.
Jedinák L., Kryštof V., Cankař P.
The Synthesis and Biological Evaluation of N-Substituted 1H-Benzimidazol-2-yl-1H-pyrazole-3,5-diamines.
Journal of Heterocyclic Chemistry.
2016.
Vymětalová L., Havlíček L., Šturc A., Bučková Z., Jorda R., Pospíšil T., Strnad M., Kryštof V.
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
European Journal of Medicinal Chemistry.
2016.
Malínková V., Vylíčil J., Kryštof V.
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014).
Expert Opinion on Therapeutic Patents.
2015.
Mrozek-Wilczkiewicz A., Spaczynska E., Malarz K., Cieslik W., Rams-Baron M., Kryštof V., Musiol R.
Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action.
PLoS One.
2015.
Řezníčková E., Weitensteiner S., Havlíček L., Jorda R., Gucký T., Berka K., Bazgier V., Zahler S., Kryštof V., Strnad M.
Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Chemical Biology and Drug Design.
2015.
Mojzych M., Karczmarzyk Z., Wysocki W., Ceruso M., Supuran CT., Kryštof V., Urbanczyk-Lipkowska Z., Kalicki P.
New approaches to the synthesis of sildenafil analogues and their enzyme inhibitory activity.
Bioorganic & Medicinal Chemistry.
2015.
Jorda R., Schütznerová E., Cankař P., Brychtová V., Navrátilová J., Kryštof V.
Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Bioorganic & Medicinal Chemistry.
2015.
Vymětalová L., Kryštof V.
Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.
Medicinal Research Reviews.
2015.
Vanda D., Jorda R., Lemrová B., Volná T., Kryštof V., Mcmaster C., Soural M.
Synthesis of Novel N-9-Substituted Purine Derivatives from Polymer Supported alpha-Amino Acids.
ACS Combinatorial Science.
2015.
Vanda D., Jorda R., Lemrová B., Volná T., Kryštof V., Mcmaster C., Soural M.
Synthesis of novel N9-substituted purine derivatives from polymer supported α-amino acids.
ACS Combinatorial Science.
2015.
Havlíček L., Moravcová D., Kryštof V., Strnad M.
The Identification of a Novel Highly Condensed Pentacyclic Heteroaromatic Ring System 1,3,5,5b,6,8,10,10b-Octaazacyclopenta[h,i]Aceanthrylene and its Application in the Synthesis of 5,7-Substituted Pyrazolo[4,3-d]Pyrimidines.
Journal of Heterocyclic Chemistry.
2015.
Řezníčková E., Popa A., Gucký T., Zatloukal M., Havlíček L., Bazgier V., Berka K., Jorda R., Popa I., Nasereddin A., Jaffe CL., Kryštof V., Strnad M.
2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro.
Bioorganic & Medicinal Chemistry Letters.
2015.
Jorda R., Navrátilová J., Hušková Z., Schütznerová E., Cankař P., Strnad M., Kryštof V.
Arylazopyrazole AAP1742 Inhibits CDKs and Induces Apoptosis in Multiple Myeloma Cells via Mcl-1 Downregulation.
Chemical Biology and Drug Design.
2014.
Holčáková J., Muller P., Tomasec P., Hrstka R., Nekulová M., Kryštof V., Strnad M., Wilkinson GWG., Vojtěšek B.
Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
PLoS One.
2014.
Jedinák L., Kryštof V., Trávníček Z., Cankař P.
Multicomponent and Regioselective Synthesis of Dihydropyrazolopyrimidines from Aromatic Aldehydes, Meldrum’s Acid, and Aminopyrazole CAN508.
Heterocycles.
2014.
Mojzych M., Šubertová V., Bielawska A., Bielawski K., Bazgier V., Berka K., Gucký T., Fornal E., Kryštof V.
Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
European Journal of Medicinal Chemistry.
2014.
Vilkauskaite G., Schaaf P., Sackus A., Kryštof V., Holzer W.
Synthesis of pyridyl substituted pyrazolo[4,3-c]pyridines as potential inhibitors of protein kinases.
Arkivoc.
2014.
Gucký T., Jorda R., Zatloukal M., Bazgier V., Berka K., Řezníčková E., Béres T., Strnad M., Kryštof V.
A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors.
Journal of Medicinal Chemistry.
2013.
Haider C., Grubinger M., Řezníčková E., Weiss T., Rotheneder H., Miklos W., Berger W., Jorda R., Zatloukal M., Gucký T., Strnad M., Kryštof V., Mikulits W.
Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance.
Molecular Cancer Therapeutics.
2013.
Imramovský A., Jorda R., Pauk K., Řezníčková E., Dušek J., Hanušek J., Kryštof V.
Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines.
European Journal of Medicinal Chemistry.
2013.
Dolečková I., Česnek M., Dračinský M., Brynda J., Voller J., Janeba Z., Kryštof V.
Synthesis and biological evaluation of guanidino analogues of roscovitine.
European Journal of Medicinal Chemistry.
2013.
Zatloukal M., Jorda R., Gucký T., Řezníčková E., Voller J., Pospíšil T., Malínková V., Adamcová H., Kryštof V., Strnad M.
Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
European Journal of Medicinal Chemistry.
2013.
Weitensteiner SB., Liebl J., Kryštof V., Havlíček L., Gucký T., Strnad M., Fuerst R., Vollmar AM., Zahler S.
Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors.
PLoS One.
2013.
Dolečková I., Rárová L., Grúz J., Vondrusová M., Strnad M., Kryštof V.
Antiproliferative and antiangiogenic effects of flavone eupatorin, an active constituent of chloroform extract of Orthosiphon stamineus leaves.
Fitoterapia.
2012.
Rárová L., Zahler S., Liebl J., Kryštof V., Sedlák D., Bartůněk P., Kohout L., Strnad M.
Brassinosteroids inhibit in vitro angiogenesis in human endothelial cells.
Steroids.
2012.
Jorda R., Paruch K., Kryštof V.
Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres.
Current Pharmaceutical Design.
2012.
Wang K., Hampson P., Hazeldine J., Kryštof V., Strnad M., Pechan P., Lord JM.
Cyclin-Dependent Kinase 9 Activity Regulates Neutrophil Spontaneous Apoptosis.
PLoS One.
2012.
Kryštof V., Baumli S., Fuerst R.
Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target.
Current Pharmaceutical Design.
2012.
Schütznerová E., Popa I., Kryštof V., Koshino H., Trávníček Z., Hradil P., Cankař P.
Utilization of DmbNHNH2 in the synthesis of amino-substituted 4-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenols.
Tetrahedron.
2012.
Liebl J., Kryštof V., Vereb G., Takac L., Strnad M., Pechan P., Havlíček L., Zatloukal M., Fuerst R., Vollmar A., Zahler S.
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Angiogenesis.
2011.
JORDA R., Sacerdoti-Sierra N., VOLLER J., HAVLÍČEK L., Kracalíková K., Nowicki M., Nasereddin A., KRYŠTOF V., STRNAD M., Walkinshaw M., Jaffe C.
Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines.
Bioorganic & Medicinal Chemistry Letters.
2011.
JORDA R., HAVLÍČEK L., McNae I., Walkinshaw M., VOLLER J., Šturc A., Navrátilová J., Kuzma M., MISTRÍK M., BÁRTEK J., STRNAD M., Kryštof V.
Pyrazolo[4,3-d]pyrimidine Bioisostere of Roscovitine: Evaluation of a Novel Selective Inhibitor of Cyclin-Dependent Kinases with Antiproliferative Activity.
Journal of Medicinal Chemistry.
2011.
KRYŠTOF V., RÁROVÁ L., Liebl J., Zahler S., JORDA R., VOLLER J., CANKAŘ P.
The selective P-TEFb inhibitor CAN508 targets angiogenesis.
European Journal of Medicinal Chemistry.
2011.
JEDINÁK L., KRYŠTOF V., CANKAŘ P.
The Synthesis of Some Derivatives Based on the 4-Benzyl-1H-pyrazole-3,5-diamine Core.
Heterocycles.
2011.
Voller J., Zatloukal M., Lenobel R., Doležal K., Béreš T., Kryštof V., Spíchal L., Niemann P., Džubák P., Hajdúch M., Strnad M.
Anticancer activity of natural cytokinins: a structure-activity relationship study.
Phytochemistry.
2010.
Koledová Z., Rašková Kafková L., Calábková L., Kryštof V., Doležel P., Divoký V.
Cdk2 Inhibition Prolongs G1 Phase Progression in Mouse Embryonic Stem Cells.
Stem Cells and Development.
2010.
Kryštof V., Uldrijan S.
Cyclin-dependent kinase inhibitors as anticancer drugs.
Current Drug Targets.
2010.
Kryštof V., Chamrád I., Jorda R., Kohoutek J.
Pharmacological targeting of CDK9 in cardiac hypertrophy.
Medicinal Research Reviews.
2010.
Gucký T., Řezníčková E., Džubák P., Hajdúch M., Kryštof V.
Synthesis and anticancer activity of some 1,5-diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines.
Monatshefte für Chemie.
2010.
Trávníček Z., Popa I., Čajan M., Zbořil R., Kryštof V., Mikulík J.
The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic, spectroscopic (IR, ES+ MS, NMR, 57Fe Mössbauer), theoretical, and biological activity studies.
Journal of Inorganic Biochemistry.
2010.
Holčáková J., Tomašec P., Burget JJ., Wang EC., Wilkinson GW., Hrstka R., Kryštof V., Strnad M., Vojtěšek B.
The Inhibitor of Cyclin-dependent Kinases Olomoucine II Exhibits Potent Antiviral Properties.
Antiviral Chemistry & Chemotherapy.
2010.
Panáček A., Kolář M., Večeřová R., Prucek R., Soukupová J., Kryštof V., Hamal P., Zbořil R., Kvítek L.
Antifungal activity of silver nanoparticles against Candida spp.
Biomaterials.
2009.
Paprskářová M., Kryštof V., Jorda R., Džubák P., Hajdúch M., Wesierska-Gadek JA., Strnad M.
Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Journal of Cellular Biochemistry.
2009.
Paprskářová M., Kryštof V., Jorda R., Džubák P., Hajdúch M., Wesierska-Gadek J., Strnad M.
Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Journal of Cellular Biochemistry.
2009.
Węsierska-Gądek JA., Chamrád I., Kryštof V.
Novel potent pharmacological CDK inhibitors - a review of the patent literature.
Future Medicinal Chemistry.
2009.
Wesierska-Gadek J., Borza A., Walzi E., Kryštof V., Maurer M., Komina O., Wandl S.
Outcome of Treatment of Human HeLa Cervical Cancer Cells With Roscovitine Strongly Depends on the Dosage and Cell Cycle Status Prior to the Treatment.
Journal of Cellular Biochemistry.
2009.
Wesierska-Gadek J., Kryštof V.
Selective CDK inhibitors discriminating between cell cycle and transcriptional kinases: Future reality or utopia?
Annals of the New York Academy of Sciences.
2009.
Wesierska-Gadek J., Kryštof V.
Selective Cyclin-Dependent Kinase Inhibitors Discriminating between Cell Cycle and Transcriptional Kinases Future Reality or Utopia?
Annals of the New York Academy of Sciences.
2009.
Szüčová L., Spíchal L., Doležal K., Zatloukal M., Greplová J., Galuszka P., Kryštof V., Voller J., Popa I., Massino FJ., JøRgensen JE., Strnad M.
Synthesis, characterization and biological activity of ring-substituted 6-benzylamino-9-tetrahydropyran-2-yl and 9-tetrahydrofuran-2-ylpurine derivatives.
Bioorganic & Medicinal Chemistry.
2009.
Kryštof V.
Oncogenic Kinase Bcr-Abl and Its Resistance to Pharmacological Inhibitors.
Chemické listy.
2008.
Kryštof V.
Onkogenní kinasa Bcr-Abl a její rezistence k používaným inhibitorům.
Chemické listy.
2008.
Węsierska-Gądek J., Wandl S., Kramer M., Pickem C., Kryštof V., Hajek SB.
Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
Journal of Cellular Biochemistry.
2008.
Spíchal L., Kryštof V., Paprskářová M., Lenobel R., Stýskala J., Binarová P., Cenklová V., De Veylder L., Inzé D., Kontopidis G., Fischer PM., Schmülling T., Strnad M.
Classical anticytokinins do not interact with cytokinin receptors, but inhibit cyclin-dependent kinases.
Journal of Biological Chemistry.
2007.
Dvořák Z., Modrianský M., Vrba J., Ulrichová J., Kryštof V., Stýskala J., Pávek P.
Evaluation of novel microtubules interfering agents myoseverin, tubulyzine and E2GG in primary cultures of rat hepatocytes.
General Physiology and Biophysics.
2007.
Doležal K., Popa I., Hauserová E., Spíchal L., Chakrabarty K., Novák O., Kryštof V., Voller J., Holub J., Strnad M.
Preparation, biological activity and endogenous occurrence of N6-benzyladenosines.
Bioorganic & Medicinal Chemistry.
2007.
Cankař P., Schutznerová E., Kryštof V.
3,5-Diamino-4-pyridylazopyrazoly, inhibitory CDK.
ChemZi.
2007.
Liebl J., Kryštof V., Pechan P., Vollmar A., Zahler S.
Antiproliferative effects of new Cdk inhibitors LGR 561 and LGR 849 on endothelial cells.
Journal of Vascular Research.
2006.
Mikulík J., Trávníček Z., Popa I., Zbořil R., Kryštof V.
Komplexy Fe(III) s N6-substituovanými deriváty adenosinu: příprava, spektrální a magnetické vlastnosti, cytotoxicita.
Chemické listy.
2006.
Cankař P., Fryšová I., Slouka J., Kryštof V., Fisher P., Strnad M.
Nové selektivní inhibitory CDK.
Chemické listy.
2006.
Doležal K., Popa I., Kryštof V., Spíchal L., Fojtíková M., Holub J., Lenobel R., Schmülling T., Strnad M.
Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells.
Bioorganic & Medicinal Chemistry.
2006.
Kryštof V., Moravcová D., Paprskářová M., Barbier P., Peyrot V., Hlobilková A., Havlíček L., Strnad M.
Synthesis and biological activity of 8-azapurine and pyrazolo[4,3-d]pyrimidine analogues of myoseverin.
European Journal of Medicinal Chemistry.
2006.
Hlobilková A., Knillová J., Šváchová M., Skypalová P., Kryštof V., Kolář Z.
Tumour suppressor PTEN regulates cell cycle and protein kinase B/Akt pathway in breast cancer cells.
Anticancer Research.
2006.
Hlobilková A., Knillová J., Šváchová M., Skypalová P., Kryštof V., Kolář Z.
Tumour Suppressor PTEN Regulates Cell Cycle and Protein Kinase B/Akt Pathway in Breast Cancer Cells.
Anticancer Research.
2006.
Trávníček Z., Kryštof V., Šipl M.
Zn(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: Synthesis, characterization, X-ray structures and biological activity.
Journal of Inorganic Biochemistry.
2006.
Kryštof V., Cankař P., Fryšová I., Slouka J., Kontopidis G., Džubák P., Hajdúch M., Srovnal J., de Azevedo Jr. W. F., Orság M., Paprskářová M., Rolčík J., Látr A., Fischer P. M.., Strnad M.
4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects.
Journal of Medicinal Chemistry.
2006.
Kryštof V., Cankař P., Fryšová I., Slouka J., Kontopidis G., Džubák P., Hajdúch M., Srovnal J., de Azevedo Jr. W. F., Orság M., Paprskářová M., Rolčík J., Látr A., Fischer P. M.., Strnad M.
4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects.
Journal of Medicinal Chemistry.
2006.
Kryštof V., McNae I., Walkinshaw M., Fischer P., Müller P., Vojtěšek B., Orság M., Havlíček L., Strnad M.
Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor.
Cellular and Molecular Life Sciences.
2005.
Klanicová A., Trávníček Z., Popa I., Kryštof V.
Příprava, studium a cytotoxická aktivita dvojjaderných Cu(II) komplexů s deriváty adeninu.
ChemZi.
2005.
Havlíček L., Fuksová K., Kryštof V., Orság M., Vojtěšek B., Strnad M.
8-Azapurines as new inhibitors of cyclin-dependent kinases.
Bioorganic & Medicinal Chemistry.
2005.
Kryštof V., Orság M., Otyepka M., Vojtěšek B., Strnad M.
Antiproliferative activity of Olomoucine II, a novel cyclin-dependent kinase inhibitor.
Acta Universitatis Palackianae Olomucensis, Facultas Rerum Naturalium, Chemica.
2004.
Kryštof V., Barbier P., Peyrot V., Hlobilková A., Havlíček L., Paprskářová M., Strnad M.
Inhibition of microtubule assembly by myoseverin and its 8-aza analogue.
Anticancer Research.
2004.
Szüčová L., Trávníček Z., Zatloukal M., Kryštof V.
Komplexy Pt(II) a Pd(II) s deriváty 6-benzylaminopurinu. Příprava, charakteristika, cytotoxicita.
Chemické listy.
2004.
Kryštof V., Cankař P., Fryšová I., Slouka J., Otyepka M., Rolčík J., Látr A., Strnad M.
Nová skupina inhibitorů cyklin-dependentních kinas: 4-arylazo-3,5-diaminopyrazoly.
Chemické listy.
2004.
Kryštof V.
Pharmacological inhibitors of protein kinases.
Acta Universitatis Palackianae Olomucensis, Facultas Rerum Naturalium, Chemica.
2004.
Trávníček Z., Kryštof V.
6-benzylamino-2-(2-hydroxyethylamino)-9-methylpurine-1,7-diium bis(perchlorate) monohydrate.
Acta Crystallographica Section E - Structure Reports Online.
2004.
Moravcová D., KRYŠTOF V., HAVLÍČEK L., Moravec J., LENOBEL R., Strnad M.
Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.
Bioorganic & Medicinal Chemistry Letters.
2003.
Moravcová D., Kryštof V., Havlíček L., Moravec J., Lenobel R., Strnad M.
Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.
Bioorganic & Medicinal Chemistry Letters.
2003.
Moravec J., KRYŠTOF V., Hanuš J., Havlicek L., Moravcova D., Kuzma M., LENOBEL R., OTYEPKA M., STRNAD M.
2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.
Bioorganic & Medicinal Chemistry Letters.
2003.
Moravec J., KRYŠTOF V., Hanuš J., HAVLÍČEK L., Moravcová D., Fuksová K., Kuzma M., LENOBEL R., Otyepka M., Strnad M.
2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.
Bioorganic & Medicinal Chemistry Letters.
2003.
Vermeulen K., Strnad M., Kryštof V., Havlíček L., Van der Aa A., Lenjou M., Nijs G., Rodrigus I., Stockman B., van Onckelen H., van Bockstaele D., Berneman ZB.
Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
Leukemia.
2002.
KRYŠTOF V., LENOBEL R., HAVLÍČEK L., Kuzma M., Strnad M.
Synthesis and biological activity of olomoucine II.
Bioorganic & Medicinal Chemistry Letters.
2002.
Kryštof V., Lenobel R., Havlíček L., Kuzma M., Strnad M.
Synthesis and biological activity of olomoucine II.
Bioorganic & Medicinal Chemistry Letters.
2002.
Kryštof V., Strnad M.
Inhibitory cyklin-dependentních kinas.
Chemické listy.
2001.
Maloň M., Trávníček Z., Maryško M., Zbořil R., Mašláň M., Marek J., Doležal K., Rolčík J., Kryštof V., Strnad M.
Metal complexes as anticancer agents 2. Iron (III) and copper(II) bio-active complexes with N6-benzylaminopurine derivatives.
Inorganica Chimica Acta.
2001.
Trávníček Z., Maloň M., Šindelář Z., Doležal K., Rolčík J., Kryštof V., Strnad M., Marek J.
Preparation, physicochemical properties and biological activity of copper(II) complexes with 6-(2-chlorobenzylamino)purine (HL1) or 6-(3-chlorobenzylamino)purine (HL2). The single crystal X-ray structure of [Cu(H+L2)(2)Cl-3]Cl-2H(2)O.
Journal of Inorganic Biochemistry.
2001.
PŘÍSPĚVEK VE SBORNÍKU
Cankař P., Kryštof V.
4-Arylazo-3,5-diamino-1H-pyrazoles: Development of CDK9 inhibitors.
Frontiers in CNS and Oncology Medicinal Chemistry.
2007.
Strnad M., Doležal K., Popa I., Zatloukal M., Lenobel R., Binarová P., Kryštof V., Havlíček L.
New cytokinin derivatives for agriculture and medicine.
18th IPGSA conference, Conference Handbook.
2004.
Havlíček L., Kryštof V., Lenobel R., Strnad M.
New heterocyclic compounds with strong CDK inhibitory and anticancer properties.
Cell Cycle and Cancer: Pathways and Therapies.
2004.
Kryštof V., Orság M., Paprskářová M., Havlíček L., Vojtěšek B., Fischer PM., McNae IW., Walkinshaw MD., Strnad M.
Olomoucine II, a novel cyclin-dependent kinase inhibitor, induces strong p53-dependent transcription.
Cell Cycle and Cancer: Pathways and Therapies.
2004.
Strnad M., Kryštof V., Spíchal L., Havlíček L., Cenklová V., Binarová P.
The Effects of Inhibitors of Cyclin-Dependent Kinases on Plant Cells.
10th Days of Plant Physiology.
2004.
KAPITOLA V KNIZE
Węsierskia-Gądek J., Maurer M., Komina O., Krammer P., Wandl S., Kryštof V., Schmid G.
Control of the proper cell cycle progression by products of the tumor suppressor gene p53 and inhibitors of cyclin-dependent kinases. Use of pharmacological inhibitors mimicking the action of cell cycle regulators for cancer therapy.
Trends in Cell Cycle Research.
2008.
PATENT, UŽITNÝ VZOR, PRŮMYSLOVÝ VZOR
Žukauskaite A., Simerská H., Strnad M., Kryštof V., Malina L., Hošíková B., Kolářová H., VARVUOLYTE G., BIELIAUSKAS A., KLEIZIENE N., ARBACIAUSKIENE E., SACKUS A.
Pyrazole indole conjugates for photodynamic treatment of cancer and bacterial infections.
2023.
Varvuolyte G., Malina L., Bieliauskas A., Hošíková B., Simerská H., Kolářová H., Kleiziene N., Strnad M., Arbačiauskiene E., Kryštof V., Šačkus A., Žukauskaite A.
Pyrazol-indolové konjugáty pro fotodynamickou léčbu rakoviny a bakteriálních infekcí.
2021.
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V.
2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions.
2021.
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V.
2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions.
2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M.
5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-D]pyrimidines for treatment of lymphoma.
2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M.
5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-D]pyrimidines for treatment of lymphoma.
2021.
Havlíček L., Šturc A., Řezníčková E., Jorda R., Kryštof V., Strnad M.
5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů.
2020.
Gucký T., Řezníčková E., Jorda R., Divoký V., Kryštof V., Radošová Muchová T., Strnad M.
2,6-disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky.
2019.
Havlíček L., Šturc A., Kryštof V., Jorda R., Pospíšil T., Zahler S., Vollmar A., Strnad M.
5-substituted 7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo[4,3-D]pyrimidine derivatives, use thereof as medicaments and pharmaceutical compositions.
2019.
Havlíček L., Šturc A., Kryštof V., Jorda R., Pospíšil T., Zahler S., Vollmar A., Strnad M.
5-substituted 7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo4,3-D]pyrimidine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2018.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
ПРОИЗВОДНЫЕ 2-ЗАМЕЩЕННЫХ-6-БИАРИЛМЕТИЛАМИНО-9-ЦИКЛОПЕНТИЛ-9Н-ПУРИНОВ, ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ И ФАРМАЦЕВТИЧЕСКИХ СОСТАВОВ.
2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
N2-substituted-N6-(6-aryl-pyridine-3-ylmethyl)-9-cyclopentyl-9H-purine-2,6-diamine derivatives as tumor suppressor p53 activators for inhibiting angiogenesis and for treating cancer.
2017.
Zatloukal M., Kryštof V., Havlíček L., Popa I., Doležal K., Strnad M., Jorda R.
Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives.
2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-Substituované-6-biarylmethyalmino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující.
2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Strnad M., Mikulits W., Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Strnad M., Mikulits W.
2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions.
2016.
Havlíček L., Kryštof V., Zatloukal M., Doležal K., Vojtěšek B., Strnad M.
Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds.
2015.
Szüčová L., Kryštof V., Zatloukal M., Doležal K., Strnad M., Spíchal L.
Substituted 6-(benzylamino)purine riboside derivatives, use thereof and compositions containing these derivatives.
2014.
Havlíček L., Kryštof V., Zatloukal M., Doležal K., Vojtěšek B., Strnad M.
Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds.
2014.
Zatloukal M., Kryštof V., Havlíček L., Popa I., Doležal K., Strnad M., Jorda R.
Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives.
2013.
Cankař P., Fryšová I., Kryštof V., Lenobel R., Slouka J., Strnad M., Fischer PM.
4-arylazo-3,5-diamino-pyrazole compounds and use thereof.
2013.
Moravcová D., Havlíček L., Kryštof V., Lenobel R., Binarová P., Mlejnek P., Vojtěšek B., Uldrijan S., Schmülling T., Strnad M.
Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use.
2012.
Szüčová L., Kryštof V., Zatloukal M., Doležal K., Strnad M., Spíchal L.
Substituted 6-(benzylamino)purine riboside derivatives, use thereof and compositions containing these derivatives.
2012.
Havlíček L., Kryštof V., Zatloukal M., Doležal K., Strnad M., Vojtěšek B.
Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds.
2012.
ZATLOUKAL M., KRYŠTOF V., Havlíček L., POPA I., DOLEŽAL K., STRNAD M., JORDA R.
Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující.
2011.
Moravcová D., Havlíček L., Kryštof V., Lenobel R., Strnad M.
Novel pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy.
2010.
Moravcová D., Havlíček L., Kryštof V., Lenobel R., Binarová P., Mlejnek P., Vojtěšek B., Uldrijan S., Schmulling T., Strnad M.
Pyrazolo[4,3-D]pyrimidines, process for their preparation and methods of use.
2010.
Moravcová D., Havlíček L., Kryštof V., Lenobel R., Strnad M.
Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy.
2010.
Moravcová D., Strnad M., Havlíček L., Kryštof V., Lenobel R.
Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy.
2010.
Havlíček L., Kryštof V., Zatloukal M., Doležal K., Strnad M., Vojtěšek B.
Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léčiva a přípravky tyto sloučeniny obsahující.
2010.
Fuksová K., Havlíček L., Kryštof V., Lenobel R., Strnad M.
Substituted [1,2,3]triazolo[4,5-D]pyrimidines as CDK inhibitors.
2010.
Cankař P., Fryšová I., Kryštof V., Lenobel R., Slouka J., Strnad M., Fisher P.
4-arylazo-3,5-diamino-pyrazole compounds and use thereof.
Univerzita Palackého v Olomouci, Ústav Experimentální Botaniky AV ČR.
2009.
Fuksová K., Havlíček L., Kryštof V., Lenobel R., Strnad M.
Azapurine derivatives.
Ústav experimentální botaniky AV ČR.
2006.
Havlíček L., Kryštof V., Siglerová V., Lenobel R., van Onckelen H., Berneman N., Slegers H., Esmans E., Strnad M., Vermeulen K.
Purine derivatives, process for their preparation and use thereof.
Universitatire Instelling Antwerpen, Ústav Experimentální Botaniky, AV ČR.
2006.
Havlíček L., Kryštof V., Siglerová V., Lenobel R., Van Onckelen H., Berneman N., Slegers H., Esmans E., Strnad M., Vermuelen K.
Purine derivatives, process for their preparation and use thereof.
Universitaire Instelling Antwerpen (BE); Ústav experimentální botaniky AV ČR (CZ).
2006.
Cankař P., Fryšová I., Kryštof V., Lenobel R., Slouka J., Strnad M., Fischer P.
4-Arylazo-3,5-diaminopyrazole compounds and their preparation, pharmaceutical compositions, inhibition of cyclin-dependent kinases and treatment of proliferative and viral disorders.
Institute of Experimental Botany of the Academy of Sciences of the Czech Republic; Cyclacel Limited.
2006.
Fuksová K., Havlíček L., Kryštof V., Lenobel R., Strnad M.
Azapurine derivatives.
Univerzita Palackého v Olomouci.
2004.
Moravcová D., Havlíček L., Kryštof V., Lenobel R., Binarová P., Mlejnek P., Vojtěšek B., Uldrijan S., Schmülling T., Strnad M.
Pyrazolo [4, 3-D]pyrimidines, processes for their preparation and methods of use.
Univerzita Palackého v Olomouci.
2004.
ABSTRAKT
Niederlová N., Kořalková P., Chaloupková P., Janotka Ľ., Hradilová I., Gurský J., Šoucová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Belickova M., Votavova H., Kryštof V., Divoký V.
Anti-leukemic Efficacy of a Novel Inhibitor for KMT2A-r/FLT3-Driven AML via Multi-kinase Targeting and Synergy with Menin Inhibition.
Blood.
2025.
Niederlová N., Kořalková P., Chaloupková P., Janotka Ľ., Hradilová I., Gurský J., Šoucová B., Urbánková H., Řezníčková E., Gucký T., Myslivcova D., Belickova M., Votavová H., Kryštof V., Divoký V.
LGR3922: A Unique Multi-Kinase Inhibitor for KMT2A/FLT3-Driven AML Synergizing with Menin Inhibition.
7th INTERNATIONAL CONFERENCE ACUTE MYELOID LEUKEMIA “MOLECULAR AND TRANSLATIONAL” ADVANCES IN BIOLOGY AND TREATMENT (abstract book).
2025.
Löffelmann M., Škrott Z., Majera D., Štarha P., Kryštof V., Mistrík M.
Novel Dithiocarbamate-Copper Complexes Target p97/NPL4 System in Cancer Cells.
IMTM REACTOR.
2023.
Kořalková P., Niederlová N., Hradilová I., Gurský J., Chaloupková P., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V.
Targeting of SFK and CAMK Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations.
Hematologie 2023.
2023.
Niederlová N., Kořalková P., Chaloupková P., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V.
Targeting of tyrosine kinases contributing to KMT2A-r mediated leukemogenesis as a therapeutic approach in mixed-lineage leukemia.
Czech Annual Cancer Research Meeting (abstract book).
2023.
Niederlová N., Kořalková P., Chaloupková P., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V.
Unique kinase inhibitor targeting specifically MLL/FLT3-mediated signaling for personalized medicine in AML.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION.
2023.
Kořalková P., Niederlová N., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcova D., Belickova M., Kryštof V., Divoký V.
Targeting of SFK and G6PD Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations.
Blood.
2022.
Voller J., Zahajská L., Plíhalová L., Jeřábková J., Burget D., Pataki AC., Zatloukal M., Kryštof V., Brábek J., Rösel D., Doležal K., Strnad M.
6-Substituted purines as ROCK inhibitors with anti-metastatic activity.
ABSTRACT BOOK XIV. DIAGNOSTIC, PREDICTIVE AND EXPERIMENTAL ONCOLOGY DAYS.
2018.
Radošová Muchová T., Řezníčková E., Somíková Z., Gucký T., Strnad M., Kryštof V., Divoký V.
A Novel Dual Class III/Src Family Tyrosine Kinase Inhibitor Is Highly Active Against FLT3-ITD Leukemia Cells In Vivo.
Blood (online).
2016.
Weitensteiner S., Liebl J., Kryštof V., Pechan P., Fuerst R., Vollmar A., Zahler S.
Novel Cdk inhibitors as potential anti-angiogenic compounds.
Naunyn-Schmiedeberg's Archives of Pharmacology.
2011.
Řezníčková E., Jorda R., Kryštof V., Havlíček L., Strnad M.
A novel pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases: antiproliferative and proapoptotic effects.
European Journal of Cancer. Supplement.
2010.
Jorda R., Řezníčková E., Kryštof V., Havlíček L., Strnad M.
A novel pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases: antiproliferative and proapoptotic effects.
European Journal of Cancer. Supplement.
2010.
Koledová Z., Rašková Kafková L., Calábková L., Kryštof V., Divoký V.
Cyclin-dependent kinase 2 activity regulates G1 phase duration in mouse embryonic stem cells.
XIII. Setkání biochemiků a molekulárních biologů.
2009.
Koledová Z., Rašková Kafková L., Calábková L., Kryštof V., Doležel P., Divoký V.
Downregulation of Cdk2 establishes somatic cell-like cell cycle in mouse embryonic stem cells.
Stem Cells 2009 Antigua, November 19-22, 2009.
2009.
Koledová Z., Rašková Kafková L., Calábková L., Kryštof V., Doležel P., Divoký V.
Inhibícia Cdk2 kinázy indukuje diferenciáciu myších embryonálnych kmeňových buniek.
Konference vědeckých prací studentů DSP 2009.
2009.
Kryštof V., Paprskářová M., Strnad M.
Active p53 contributes to antitumor effects of cyclin-dependent kinase inhibitor roscovitine in multiple myeloma cells.
European Journal of Cancer. Supplement.
2008.
Jorda R., Kryštof V., Havlíček L., Strnad M.
Biochemical and cellular effects of a novel cyclin-dependent kinase inhibitor.
European Journal of Cancer. Supplement.
2008.
Strnad M., Kryštof V., Havlíček L., Swaczynová J.
New anticancer drugs derived from plant hormones.
Planta Medica.
2008.
Cankař P., Kryštof V.
Syntéza derivátů 3,5-diaminopyrazolů s potencionální biologickou aktivitou na CDK9.
Chemické listy.
2008.
Liebl J., Kryštof V., Pechal P., Vollmar AM., Zahler S.
Anti-angiogenic effects of new CDK inhibitors LGR 561, LGR 848, and LGR 849 on endothelial cells.
Naunyn-Schmiedeberg's Archives of Pharmacology.
2007.
Džubák P., Kryštof V., Cankař P., Fryšová I., Slouka J., Kontopidis G., Vydra D., Srovnal J., Azevedo W., Orság M., Paprskářová M., Rolčík J., Látr A., Fischer P., Strnad M., Hajdúch M.
4-Arylazo-3,5-diamino 1H pyrazolové CDK Inhibitory: analýzy in vitro a in vivo protinádorové aktivity.
Edukační sborník, XXXI. Brněnské onkologické dny.
2007.
Václavíková K., Tarkowski P., Spíchal L., Galuszka P., Kryštof V., Novák O., Doležal K.
Cytokinins in tRNA of higher plants.
Future Trends in Phytochemistry: A Young Scientists Symposium.
2006.
Strnad M., Havlíček L., Kryštof V., Hanuš J., Spíchal L., Moravcová D., Moravec J., Zatloukal M., Popa I., Paprskářová M., Orság M., Otyepka M., Hajdúch M., Džubák P., Kolář Z., Binarová P., Cenklová V.
Purine inhibitors of cyclin-dependent kinases as new generation of anticancer drugs.
Biomedical Papers-Olomouc.
2006.
Kryštof V., Müller P., Orság M., Džubák P., Hajdúch M., Parskářová M., Vojtěšek B., Strnad M.
Inhibitor cyklin-dependentních kinas olomoucin II interaguje s CDK2 a CDK9.
Sborník abstraktů. Analytická cytometrie III.
2005.
Kryštof V., Barbier P., Peyrot V., Hlobilková A., Havlíček L., Paprskářová M., Strnad M.
Inhibition of microtubule assembly by myoseverin and its 8-AZA analogue.
7th International Conference of Anticancer Research.
2004.
Kryštof V., Barbier P., Peyrot V., Hlobilková A., Havlíček L., Paprskářová M., Strnad M.
Inhibition of microtubule assembly by myoseverin and its 8-AZA analogue.
7th International Conference of Anticancer Research.
2004.
PŘEDNÁŠKA NEBO POSTER
Štarha P., Řezníčková E., Křikavová R., Milde D., Jewula P., Kryštof V.
CO2-responsive NADH oxidation by half-sandwich Ir(III) complexes - a curiosity or a problem for cancer cells?
2023.
Kryštof V., Havlíček L., Cankař P., Strnad M.
PHARMACOLOGICAL INHIBITORS OF PROTEIN KINASES: SCREENING AND DEVELOPMENT.
2007.
Cankař P., Kryštof V., Fryšová I., Slouka J., Džubák P., Hajdúch M., Orság M., Strnad M.
4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors.
4th Euroasian Meeting on Heterocyclic Chemistry - sborník.
2006.
Kryštof V., Džubák P., Hajdúch M., Cankař P., Slouka J., Paprskářová M., Jakub R.
.
57. zjazd chemických společnosti.
2005.
PROTOTYP, FUNKČNÍ VZOREK
Gucký T., Řezníčková E., Malínková V., Kryštof V.
Soubor purinových inhibitorů FLT3-ITD kinázy.
2018.
SOFTWARE
FÜRST T., KRYŠTOF V.
Software for Quantitative Analysis of Endothelial Cell Tube Formation.
2011.
SERIÁLOVÁ PUBLIKACE
..
60. Jubilejní sjezd Asociací českých a slovenských chemických společností.
In Kryštof V., Tarkowski P. (Eds.)
Chemické listy.
2008.
Aktuálně vyučované předměty
| název předmětu | katedra/zkratka | semestr | typ | hodin |
|---|---|---|---|---|
| Buněčný cyklus a apoptóza | KEB/BUCY | ZS | Př | 2 |
| Informační zdroje v biologii a medicíně | KEB/IZVBM | ZS | Se | 2 |
| Informační zdroje v biologii a medicíně | KEB/IZVBM | ZS | Př | 1 |
| Informační zdroje v biologii a medicíně | KEB/IZVB | ZS | Př | 1 |
| Informační zdroje v biologii a medicíně | KEB/IZVB | ZS | Se | 2 |
| Oborový seminář 6 | KEB/OBSE6 | LS | Se | 2 |
| Pokročilý oborový seminář 4 | KEB/OS4 | LS | Se | 2 |